FindTrial
Sign In

The predictive value of XRCC1, ERCC1, GSTP1, XPD and TS detection in the efficacy and toxicty of XELOX chemotherapy for colorectal cancer

The predictive value of XRCC1, ERCC1, GSTP1, XPD and TS detection in the efficacy and toxicty of XELOX chemotherapy for colorectal cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16008241
Enrollment
Unknown
Registered
2016-04-07
Start date
2016-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Case series:XELOX protocol

Sponsors

Shanghai ChangZheng Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. histopathologically confirmed colorectal adenocarcinom; 2. without distant metastasesin; 3. need to chemotherapy according to NCCN clinical practice guide; 4. aged lower than 70 years old; 5. informed consent obtained.

Exclusion criteria

Exclusion criteria: 1. with serious heart and lung disease; 2. with other malignant tumor; 3. with heavy renal inadequacy; 4. with peripheral neuropathies; 5. with blood diseases; 6. women who are pregnant or breast-feeding.

Design outcomes

Primary

MeasureTime frame
Tumor response;Toxicity;Progression-free survival;Overall Survival;—

Countries

China

Contacts

Public ContactZhiqian Hu

Shanghai ChangZheng Hospital

huzq62@hotmail.com+86 021-81885591

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026